Efficacy and safety of S-1 based adjuvant chemoradiotherapy for resected pancreatic ductal adenocarcinoma with high-risk pathological feature: a prospective, single-arm, interventional study

Efficacy and safety of S-1 based adjuvant chemoradiotherapy for resected pancreatic ductal adenocarcinoma with high-risk pathological feature: a prospective, single-arm, interventional study

Abstract. Objective:. It remains unclear whether adjuvant chemoradiotherapy (CRT) improves survival outcome of pancreatic ductal adenocarcinoma (PDAC) patients after surgery. This study aimed to investigate the efficacy and safety of tegafur/gimeracil/oteracil (S-1)-based adjuvant concurrent chemor...

Full description

Bibliographic Details
Main Authors:	Lili Wu, Yaolin Xu, Zhaochong Zeng, Yixing Chen, Yuhong Zhou, Dansong Wang, Jing Sun, Minzhi Lv, Shisuo Du, Wenhui Lou
Format:	Article
Language:	English
Published:	Wolters Kluwer Health/LWW 2022-03-01
Series:	Journal of Pancreatology
Online Access:	http://journals.lww.com/10.1097/JP9.0000000000000084

Similar Items

Additional adjuvant radiotherapy improves survival at 1 year after surgical treatment for pancreatic cancer patients with T4, N2 disease, positive resection margin, and receiving adjuvant chemotherapy
by: Lili Wu, et al.
Published: (2023-07-01)

The outcome of a multidisciplinary approach incorporating neoadjuvant chemoradiotherapy with S1 for resectable pancreatic ductal adenocarcinoma
by: Masaru Matsumura, et al.
Published: (2023-03-01)

Adjuvant Chemotherapy and Radiotherapy in Resected Pancreatic Ductal Adenocarcinoma: A Systematic Review and Clinical Practice Guideline
by: James J. Biagi, et al.
Published: (2023-07-01)

Complete Primary Pathological Response Following Neoadjuvant Treatment and Radical Resection for Pancreatic Ductal Adenocarcinoma
by: Kai Tai Derek Yeung, et al.
Published: (2024-01-01)

Obstructive sleep apnea predicts pathologic response to neoadjuvant therapy in resected pancreatic ductal adenocarcinoma
by: Sami Shoucair, et al.
Published: (2022-12-01)

Surgical Resection or Ablation for Recurrent Pancreatic Ductal Adenocarcinoma
by: Boram Lee, MD, et al.
Published: (2021-09-01)

Untargeted metabolomics characterization of the resectable pancreatic ductal adenocarcinoma
by: Ying-Ying Cao, et al.
Published: (2023-06-01)

Adjuvant chemoradiotherapy does not improve outcomes in patients with fistula-associated anal adenocarcinoma undergoing abdominoperineal resection
by: Min Wang, et al.
Published: (2022-11-01)

Prognostic value of tumor-associated N1/N2 neutrophil plasticity in patients following radical resection of pancreas ductal adenocarcinoma
by: Sami Shoucair, et al.
Published: (2022-12-01)

Survival Analysis in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Chemoradiotherapy Followed by Surgery According to the International Consensus on the 2017 Definition of Borderline Resectable Cancer
by: Aoi Hayasaki, et al.
Published: (2018-03-01)

Pancreatic Ductal Adenocarcinoma: Molecular Pathology and Predictive Biomarkers
by: Mehran Taherian, et al.
Published: (2022-09-01)

Utilising Pancreatic Exocrine Insufficiency in the Detection of Resectable Pancreatic Ductal Adenocarcinoma
by: Declan McDonnell, et al.
Published: (2023-12-01)

Robotic Vascular Resection in Pancreatic Ductal Adenocarcinoma: A Systematic Review
by: Victoria Zecchin Ferrara, et al.
Published: (2024-03-01)

Longitudinal Study of Circulating Biomarkers in Patients with Resectable Pancreatic Ductal Adenocarcinoma
by: Pablo J. Dopico, et al.
Published: (2022-03-01)

Fibroblasts as a Biological Marker for Curative Resection in Pancreatic Ductal Adenocarcinoma
by: Eriko Katsuta, et al.
Published: (2020-05-01)

Long-Term Outcomes of Venous Resections in Pancreatic Ductal Adenocarcinoma Patients
by: Martin Sillesen, MD, PhD, et al.
Published: (2022-12-01)

Adjuvant chemoradiotherapy in resected gallbladder cancer: A SEER-based study
by: Yong Jiang, et al.
Published: (2023-03-01)

Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: Role of the Radiologist and Oncologist in the Era of Precision Medicine
by: Federica Vernuccio, et al.
Published: (2021-11-01)

Early Assessment of Chemoradiotherapy Response for Locally Advanced Pancreatic Ductal Adenocarcinoma by Dynamic Contrast-Enhanced Ultrasound
by: Xiu-Yun Lu, et al.
Published: (2022-11-01)

Clinicopathological and Prognostic Value of Survivin Expression in Surgically Resected Pancreatic Ductal Adenocarcinoma
by: Christian Vay, et al.
Published: (2022-07-01)

A neoadjuvant therapy compatible prognostic staging for resected pancreatic ductal adenocarcinoma
by: Lingyu Zhu, et al.
Published: (2023-08-01)

Cachexia index as a prognostic predictor after resection of pancreatic ductal adenocarcinoma
by: Tomonari Shimagaki, et al.
Published: (2023-11-01)

Digital quantitative tissue image analysis of hypoxia in resected pancreatic ductal adenocarcinomas
by: Iram Siddiqui, et al.
Published: (2022-08-01)

Feasibility of delivering supervised exercise training following surgical resection and during adjuvant chemotherapy for pancreatic ductal adenocarcinoma (PRECISE): a case series
by: Malcolm Brown, et al.
Published: (2023-09-01)

Tumor‐associated N1 and N2 neutrophils predict prognosis in patients with resected pancreatic ductal adenocarcinoma: A preliminary study
by: Hanlin Yin, et al.
Published: (2022-12-01)

Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic adenocarcinoma
by: Craig L Slingluff, et al.
Published: (2023-12-01)

Staging Computed Tomography Parameters Predict the Need for Vein Resection during Pancreaticoduodenectomy in Resectable Pancreatic Ductal Adenocarcinoma
by: Rupaly Pande, et al.
Published: (2024-01-01)

Clinicopathological Features and Prognosis of Resected Pancreatic Ductal Adenocarcinoma Patients with Claudin-18 Overexpression
by: Sejun Park, et al.
Published: (2023-08-01)

Advances and Remaining Challenges in the Treatment for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma
by: Megan L. Sulciner, et al.
Published: (2022-08-01)

Comparison of Characteristics and Survival Rates of Resectable Pancreatic Ductal Adenocarcinoma according to Tumor Location
by: Min Kyu Sung, et al.
Published: (2021-11-01)

Current Treatment of Potentially Resectable Pancreatic Ductal Adenocarcinoma: A Medical Oncologist’s Perspective
by: Victor Hugo Fonseca de Jesus MD, MSc, et al.
Published: (2023-04-01)

Impact of Sarcopenia on Patients with Localized Pancreatic Ductal Adenocarcinoma Receiving FOLFIRINOX or Gemcitabine as Adjuvant Chemotherapy
by: Victor Mortier, et al.
Published: (2022-12-01)

THE SUBTYPES OF PANCREATIC DUCTAL ADENOCARCINOMAS
by: Apeksha Kakkar, et al.
Published: (2016-12-01)

Syndecans and Pancreatic Ductal Adenocarcinoma
by: Nausika Betriu, et al.
Published: (2021-02-01)

Prognostic Impact of Resection Margin Status on Distal Pancreatectomy for Ductal Adenocarcinoma
by: Maia Blomhoff Holm, et al.
Published: (2022-09-01)

Risk factors for early recurrence in patients with pancreatic ductal adenocarcinoma who underwent curative resection
by: Masaaki Murakawa, et al.
Published: (2023-08-01)

Specific Subtypes of Carcinoma-Associated Fibroblasts Are Correlated with Worse Survival in Resectable Pancreatic Ductal Adenocarcinoma
by: Karl Knipper, et al.
Published: (2023-03-01)

Survival Prediction after Curative Resection of Pancreatic Ductal Adenocarcinoma by Imaging-Based Intratumoral Necrosis
by: Hokun Kim, et al.
Published: (2022-11-01)

Successful resection of port site recurrence of pancreatic ductal adenocarcinoma after laparoscopic distal pancreatectomy
by: Takashi Aida, et al.
Published: (2023-03-01)

Induction Chemotherapy With FOLFIRINOX Followed by Chemoradiation With Gemcitabine in Patients With Borderline-Resectable Pancreatic Ductal Adenocarcinoma
by: Ana Acuna-Villaorduna MD, et al.
Published: (2022-10-01)